China has such a dominant position in active pharmaceutical ingredient (API) production that there is a risk it could "weaponise" access, according to a new congressional report.
The document, from the US-China Economic and Security Review Commission, warns that if China did choose to restrict access to APIs "it could deprive Americans of lifesaving medicines and cause significant harm to the US economy."...[PharmaPhorum]
